Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04523129 · ClinicalTrials.gov registry record · Phase 3
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
A Phase 3 study of Dry Eye Disease, sponsored by Novaliq.
- Completed
- Registry status
- Phase 3
- Development phase
- 834
- Enrollment target
- 20
- Study locations
NCT04523129 is a Phase 3 study of Dry Eye Disease that has completed, run by Novaliq. The registered enrollment target is 834 participants, above the 230-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (263% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT04523129, a Phase 3 study of Dry Eye Disease, has completed, sponsored by Novaliq.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 834 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this pivotal trial is to assess the efficacy, safety and tolerability of CyclASol in comparison to the vehicle for the treatment of signs and symptoms of Dry Eye Disease (DED).
Conditions Studied
Interventions
- DRUG CyclASol topical ocular, eye drops
- DRUG Vehicle topical ocular, eye drops
Study Locations (20)
California
- CYS-004 Investigational Site - Los Angeles
- CYS-004 Investigational Site - Newport Beach
- CYS-004 Investigational Site - Santa Ana
Indiana
- CYS-004 Investigational Site - Carmel
- CYS-004 Investigational Site - Indianapolis
Massachusetts
- CYS-004 Investigational Site - Andover
- CYS-004 Investigational Site - Raynham
Missouri
- CYS-004 Investigational Site - Kansas City
- CYS-004 Investigation Site - Kansas City
North Carolina
- CYS-004 Investigational Site - Raleigh
- CYS-004 Investigational Site - Shelby
Arizona
- CYS-004 Investigational Site - Phoenix
Colorado
- CYS-004 Investigational Site - Colorado Springs
Florida
- CYS-004 Investigational Site - Fort Lauderdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 834 participants |
| Start Date | 2020-12-05 |
| Est. Completion | 2021-10-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04523129
The ClinicalTrials.gov registry entry for NCT04523129 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 834 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 230-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (263% higher). The listed sponsor is Novaliq, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which CyclASol topical ocular, eye drops is the first listed.
NCT04523129 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Indiana, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04523129 about?
NCT04523129 is a clinical study titled "ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)". The objective of this pivotal trial is to assess the efficacy, safety and tolerability of CyclASol in comparison to the vehicle for the treatment of signs and symptoms of Dry Eye Disease (DED).
What is the current status of trial NCT04523129?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 834 participants. The study started on 2020-12-05. Estimated completion is 2021-10-08.
What conditions does trial NCT04523129 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT04523129?
The interventions under investigation include: CyclASol topical ocular, eye drops (DRUG), Vehicle topical ocular, eye drops (DRUG).
Who is sponsoring clinical trial NCT04523129?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04523129 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
COMPLETED · Phase 3
-
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
COMPLETED · Phase 3
-
A Study Designed to Evaluate Tear Production
COMPLETED · Phase 3
-
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.